Feature | May 14, 2014

Leadless Pacemaker Showing Promising Results After One Year

Follow-up results for Nanostim presented in late-breaking clinical trial presentation at Heart Rhythm 2014

May 14, 2014 — Vivek Reddy, M.D., director of arrhythmia services for The Mount Sinai Hospital, reported promising 12-month follow-up data showing the world's first leadless pacemaker is demonstrating overall device performance comparable to conventional pacemakers. Reddy presented the one-year LEADLESS study data findings during a late-breaking clinical trial presentation on Heart Rhythm 2014, the Heart Rhythm Society's (HRS) 35th annual scientific sessions in San Francisco.


The LEADLESS study's long-term follow-up has evaluated 32 patients with a slowed heartbeat, bradycardia, who successfully received St. Jude Medical's Nanostim leadless pacemaker at hospitals in Prague and in Amsterdam. The findings, which assessed device performance and patient outcomes through 12 months of follow-up, show pacing thresholds (0.43 volts) and sensing (10.32 mV) of the leadless pacemaker device are equivalent to those in traditional pacemakers. In addition, there was no experience of infections or failure to sense, pace or communicate with the pacemaker.


"This is the first time we've seen one-year follow-up data for this innovative, wireless cardiac pacing technology, and our results show the leadless pacemaker is comparable to traditional pacemakers," says Reddy, who is the study's co-investigator and chairman of its steering committee. "Our latest findings further support the promising performance and safety of this minimally invasive, nonsurgical pacing device. More long-term follow-up of these LEADLESS study patients will further our understanding of the potential advantages, benefits and complication risks of leadless pacemaker technology, along with additional ongoing, larger trials."


In February, Reddy was the first to implant the leadless pacemaker in the United States. The multicenter clinical trial LEADLESS II aims to further test the leadless pacemaker more widely for safety and efficacy in 670 patients at 50 centers across the United States and Canada.


The miniature-sized, leadless cardiac pacemaker is placed directly inside a patient's heart without surgery during a catheter-guided procedure through the groin via the femoral vein. The device, resembling a tiny, metal silver tube and smaller than a triple-A battery, is only a few centimeters in length, making it less than 10 percent the size of a traditional pacemaker. It works by closely monitoring the heart's electrical rhythms, and if the heartbeat is too slow it provides electrical stimulation therapy to regulate it. More than 4 million patients globally have a pacemaker, and 700,000 new patients receive one each year.


In comparison to a conventional pacemaker, the leadless pacemaker eliminates the need for a surgical pocket and no visible pacemaker device under a patient's chest skin, no incision scar on the chest, no connector wires or leads, and no restrictions on a patient's daily activities. The device's benefits may also allow for less patient discomfort, infections, and device complications and dysfunction.


The LEADLESS study was funded by St. Jude Medical, manufacturer of the Nanostim pacemaker. Reddy receives financial compensation as a consultant and advisory board member for St. Jude Medical. In addition, in 2013 he received one-time financial compensation from St. Jude Medical in the form of an option buyout relating to St. Jude Medical's acquisition of Nanostim.


For more information: www.mountsinai.org, www.sjm.com


Related Content

Itrevia 7 HF-T QP, Biotronik, CRT-D, first U.S. implantations, CLS algorithm
Feature | Cardiac Resynchronization Therapy Devices (CRT)| July 28, 2015
Biotronik announced the first patients have been successfully implanted with Itrevia HF-T QP cardiac resynchronization...
Feature | Atrial Fibrillation| July 20, 2015
A new study proves race and gender-related disparities exist in care for patients who have recently been diagnosed with...
Medtronic, Reveal Linq ICM, in-office insertion, RIO 2 study
News | Implantable Cardiac Monitor (ICM)| July 16, 2015
Medtronic plc announced the first in-office implant of its miniaturized cardiac monitor as part of the Medtronic Reveal...
Feature | Business| July 08, 2015
Sorin S.p.A. and Cyberonics Inc. unveiled LivaNova as the name of their combined company, effective at the close of...
Biosense Webster, Confidense Module, Carto, multi-electrode mapping, 3-D

Carto 3 System image courtesy of Biosense Webster

Technology | July 07, 2015
Biosense Webster Inc. announced the launch of the Confidense Module, an innovative technology that streamlines the...
idarucizumab, dabigatran, anticoagulant, Boehringer Ingelheim, RE-VERSE AD
News | Antiplatelet and Anticoagulation Therapies| July 07, 2015
Results from an interim analysis of the Phase III RE-VERSE AD patient study demonstrate that 5 g of idarucizumab...
Boston Scientific, Emblem, S-ICD, UNTOUCHED study, TV-ICDs, MADIT-RIT study
Feature | Implantable Cardioverter Defibrillators (ICD)| July 02, 2015
Boston Scientific has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with...
Medtronic, CardioInsight, acquisition, ECVUE, cardiac mapping system

Image courtesy of CardioInsight Technologies Inc.

Feature | EP Mapping and Imaging Systems| July 01, 2015
Medtronic has acquired CardioInsight Technologies Inc., a Cleveland-based medical device company that has developed a...
ACC, HRS, SCAI, left atrial appendage occlusion, recommendations
Feature | Left Atrial Appendage (LAA) Occluders| June 30, 2015
The American College of Cardiology (ACC), Heart Rhythm Society (HRS) and Society for Cardiovascular Angiography and...
Overlay Init